Tot Biopharm International Co
Tot Biopharm International Co., a leading player in the biopharmaceutical industry, is headquartered in China (CN) and operates extensively across Asia and beyond. Founded in 2016, the company has rapidly established itself as a key innovator in the development of high-quality biopharmaceutical products, particularly in the fields of oncology and autoimmune diseases. With a robust portfolio that includes monoclonal antibodies and biosimilars, Tot Biopharm distinguishes itself through its commitment to advanced research and development, ensuring that its offerings meet stringent international standards. The company has achieved significant milestones, including successful product launches and strategic partnerships, solidifying its market position as a trusted provider of biopharmaceutical solutions. Through its dedication to innovation and quality, Tot Biopharm continues to make a meaningful impact in the global healthcare landscape.
DitchCarbon Score
How does Tot Biopharm International Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Tot Biopharm International Co's score of 21 is lower than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Tot Biopharm International Co's reported carbon emissions
In 2023, Tot Biopharm International Co, headquartered in China (CN), reported total carbon emissions of approximately 15,812,000 kg CO2e. This figure includes 4,957,000 kg CO2e from Scope 1 emissions and 10,855,000 kg CO2e from Scope 2 emissions. The company has shown a commitment to transparency in its emissions reporting, with data disclosed for both Scope 1 and Scope 2. Comparatively, in 2022, Tot Biopharm's emissions were about 11,431,000 kg CO2e, comprising 4,516,000 kg CO2e from Scope 1 and 6,915,000 kg CO2e from Scope 2. This indicates a significant increase in emissions from 2022 to 2023. Despite the increase in emissions, Tot Biopharm has not set specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or commitments to frameworks such as the Science Based Targets initiative (SBTi). The company’s emissions data is not cascaded from a parent organization, ensuring that the reported figures are solely reflective of its operations. Overall, while Tot Biopharm International Co has made strides in emissions reporting, the lack of defined climate commitments or reduction targets highlights an area for potential improvement in its sustainability strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|
| Scope 1 | 3,562,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 7,757,000 | 0,000,000 | 00,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Tot Biopharm International Co is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
